Bluejay Diagnostics Reports $7.38 Million in Cash and Advances Clinical Milestones
Bluejay Diagnostics reported $7.38M in cash as of Q3 2026, up from $5.16M at year-end 2025. The company completed SYMON-II study enrollment and advanced Symphony platform manufacturing. It aims for FDA 510(k) submission in H1 2027, contingent on validation. Current funds should last until Q2 2027, with additional financing needed for long-term plans.
